Key Insights

Highlights

Treatment Research

4 treatments under study, led by Lvgn3616 Lvgn6051 Lvgn7409 Nabpaclitaxel

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05075993Phase 1Active Not RecruitingPrimary

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Showing all 1 trials

Research Network

Common Treatments

  • Lvgn3616 Lvgn6051 Lvgn7409 Nabpaclitaxel1
  • Lvgn3616 Lvgn6051 Lvgn7409 Bevacizumab Cyclophosphamide1
  • Lvgn3616 Lvgn6051 Nabpaclitaxel1
  • Lvgn3616 Lvgn6051 Bevacizumab Cyclophosphamide1

Active Sponsors

  • M.D. Anderson Cancer Center1
  • Lyvgen Biopharma Holdings Limited1

Top Investigators

Related Conditions

  • Metastatic Uveal Melanoma1
  • Gastric Cancer1
  • Metastatic Hpv Related Solid Tumors1
  • Metastatic Hepatocellular Carcinoma1
  • Metastatic Soft Tissue Sarcoma1

Activity Timeline